Cargando…

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations

Discovered by serendipity, onabotulinum toxin A (BoNT-A) is the only US Food and Drug Administration-approved treatment for the prevention of chronic migraine (CM), one of the most disabling and burdensome human conditions. Its efficacy, safety and tolerability, proved by the largest and longest mig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbanti, Piero, Ferroni, Patrizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628659/ https://www.ncbi.nlm.nih.gov/pubmed/29033605 http://dx.doi.org/10.2147/JPR.S113614

Ejemplares similares

Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)

Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients
por: Ali, Sameer S, et al.
Publicado: (2019)

The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
por: Jia, Cassie, et al.
Publicado: (2019)

Efficacy of Onabotulinum Toxin A on Obsessive–Compulsive Traits in a Population of Chronic Migraine Patients
por: Viticchi, Giovanna, et al.
Publicado: (2022)

Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012)

Patients profiling for Botox® (onabotulinum toxin A) treatment for migraine: a look at white matter lesions in the MRI as a potential marker
por: Bumb, Anja, et al.
Publicado: (2013)

Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study
por: Corbelli, Ilenia, et al.
Publicado: (2022)

Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
por: García-Azorín, David, et al.
Publicado: (2022)

EHMTI-0278. Onabotulinum toxin a for hemicrania continua: a case series of 8 patients
por: Miller, S, et al.
Publicado: (2014)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
por: Trinh, Hamilton, et al.
Publicado: (2019)

Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations
por: Shafqat, Rafia, et al.
Publicado: (2020)

Onabotulinum toxin-A (Botox) for spastic equinus in cerebral palsy: a prospective kinematic study
por: Hastings-Ison, T., et al.
Publicado: (2018)

Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine
por: Sarchielli, Paola, et al.
Publicado: (2017)

New Injection Points of Onabotulinum Toxin A for Spastic Paralysis of the Fingers: Eight Cases of Report
por: Yamada, Shoko Merrit, et al.
Publicado: (2020)

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations
por: Keskin, Dilek, et al.
Publicado: (2016)

Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment
por: Tarcan, Tufan, et al.
Publicado: (2014)

Machine learning approach to predict medication overuse in migraine patients
por: Ferroni, Patrizia, et al.
Publicado: (2020)

Association of LTA and SOD Gene Polymorphisms with Cerebral White Matter Hyperintensities in Migraine Patients
por: Ferroni, Patrizia, et al.
Publicado: (2022)

Long‐Term Outcome of Patients With Intractable Chronic Cluster Headache Treated With Injection of Onabotulinum Toxin A Toward the Sphenopalatine Ganglion – An Observational Study
por: Aschehoug, Irina, et al.
Publicado: (2018)

Pelvic-Spinal Analysis and the Impact of Onabotulinum toxin A Injections on Spinal Balance in one Child With Cerebral Palsy
por: Chaléat-Valayer, Emmanuelle, et al.
Publicado: (2016)

Bladder diverticuli following injection of onabotulinum toxin A in a patient with multiple sclerosis and autosomal dominant polycystic kidney disease
por: Raza, Syed Imran, et al.
Publicado: (2018)

Non-surgical Brachioplexy Using Polydioxanone Threads and Onabotulinum Toxin Type A in an Indian Female Patient: A Case Report
por: Arora, Reema Tebak, et al.
Publicado: (2022)

Chronic migraine: treatability, refractoriness, pseudo-refractoriness
por: Barbanti, Piero, et al.
Publicado: (2015)

Cryolipolysis: patient selection and special considerations
por: Meyer, Patricia Froes, et al.
Publicado: (2018)

Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis
por: El Kahky, Hanan Mohamed, et al.
Publicado: (2013)

Endoscopic bronchial valve treatment: patient selection and special considerations
por: Eberhardt, Ralf, et al.
Publicado: (2015)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
por: Blum, Sabine, et al.
Publicado: (2016)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
por: Petrini, Iacopo, et al.
Publicado: (2022)

Repeated onabotulinum neurotoxin A injections for drooling in children with neurodisability
por: Bekkers, Stijn, et al.
Publicado: (2021)

Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study
por: De Rienzo, Gaetano, et al.
Publicado: (2021)

Lung transplantation in chronic obstructive pulmonary disease: patient selection and special considerations
por: Lane, C Randall, et al.
Publicado: (2015)

Tympanostomy tubes: patient selection and special considerations
por: Whittemore, Kenneth R
Publicado: (2015)

Treatment of lateral canthal rhytides with a medium depth chemical peel with or without pretreatment with onabotulinum toxin type A: a randomized control trial
por: Tung, Rebecca, et al.
Publicado: (2016)

Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
por: Debaillon Vesque, Audrey, et al.
Publicado: (2020)

Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
por: Montazeri, Kamaneh, et al.
Publicado: (2023)

Management considerations in the treatment of migraine in adolescents
por: Matarese, Christine A, et al.
Publicado: (2010)

Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations
por: Lutz, Jens, et al.
Publicado: (2017)

Onabotulinum Toxin A Intradetrusor Injections in Children with Neurogenic Lower Urinary Tract Dysfunction: Long-Term Histological Effects on the Bladder Wall
por: Pellegrino, Chiara, et al.
Publicado: (2023)

Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations
por: Chao, Ariana M, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ik52an2vpq2elkbnht84nuug3a